Each of the drug applicants acts by a unique mechanism of action and gets the potential to target a wide range of cancers types. We believe this transaction will instantly strengthen our drug pipeline, enhancing Access’ franchise value within the oncology space, commented Stephen R. Seiler, Gain access to’ President and CEO. In addition to offering a clinical-stage drugcandidate, Somanta’s pre-scientific pipeline is highly diversified with each anti-cancer compound having its own novel mode of action, which can be applied to an array of cancer types. and.. Access Somanta and Pharmaceuticals Pharmaceuticals sign merger agreement Gain access to Pharmaceuticals and Somanta Pharmaceuticals have announced that they have signed a definitive merger agreement by which Access will acquire Somanta.Despite the fact that circulating testosterone amounts are low in these patients, the androgen receptor reactivates, which indicates the AR continues to be a significant target in CRPC. The Rotterdam-based group has previously demonstrated that conversion of adrenal androgens into testosterone, instead of intratumoural de novo steroidogenesis, is the major source of testosterone in CRPC tumours. Clinical trials possess demonstrated that abiraterone acetate plus prednisone/prednisolone can increase survival in CRPC sufferers even after chemotherapy.